

THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer A Disintegrin and Metalloproteinase with Thrombospondin Motifs-4 (ADAMTS-4) levels in chondrocytes of different morphology within non-degenerate and early osteoarthritic human femoral head cartilage

Citation for published version:

Herren, AOF, Amin, AK & Hall, AC 2023, 'A Disintegrin and Metalloproteinase with Thrombospondin Motifs-4 (ADAMTS-4) levels in chondrocytes of different morphology within non-degenerate and early osteoarthritic human femoral head cartilage', Cartilage. https://doi.org/10.1177/19476035231176532

Digital Object Identifier (DOI):

10.1177/19476035231176532

Link:

Link to publication record in Edinburgh Research Explorer

Document Version: Peer reviewed version

Published In: Cartilage

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Cartilage

Cartilage

A Disintegrin and Metalloproteinase with Thrombospondin Motifs-4 (ADAMTS-4) levels in chondrocytes of different morphology within non-degenerate and early osteoarthritic human femoral head cartilage.

Journal:	Cartilage
Manuscript ID	Draft
Manuscript Type:	Basic Research Article
Keywords:	chondrocyte, Osteoarthritis < Diagnosis, ADAMTS-4
Abstract:	Short Communication



Cartilage

A Disintegrin and Metalloproteinase with Thrombospondin Motifs-4 (ADAMTS-4) levels in chondrocytes of different morphology within non-degenerate and early osteoarthritic human femoral head cartilage.

Introduction and Summary.

Osteoarthritis (OA) is a common degenerative disorder affecting whole synovial joints. Characteristic features include progressive loss of mechanically-weakened cartilage which eventually exposes sub-chondral bone, and movement results in extreme pain and ultimately joint failure¹. Understanding early extracellular matrix (ECM) damage is a key research objective with aggrecan degradation a hallmark of OA². Early OA shows strong immunostaining for the major proinflammatory cytokines IL-1 β and TNF- α suggesting an important role in OA³. These stimulate production of two groups of proteolytic enzymes, the MMPs (metalloproteinases) and the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) family both which cause aggrecan degradation. ADAMTS-4 (aggrecanase-1⁴) and ADAMTS-5 have been implicated since aggrecan fragments in OA match those produced by these enzymes⁵. ADAMTS-4 is induced by IL- β and TNF- α whereas ADAMTS-5 is constitutively expressed in normal cartilage⁶. Relative mRNA levels of ADAMTS-4 are ~4-fold higher in knee OA compared to normal cartilage and correlate with degenerative progression⁷. However, inhibitory elements may be upregulated and posttranscriptional modifications occur, so this does not necessarily constitute higher ADAMTS-4 protein levels. Although ADAMTS-4 knockouts showed no effect against cartilage degeneration in an animal instability model⁸, the pathway(s) for cartilage loss in idiopathic human OA may be different.

Early microscopic changes to chondrocytes in otherwise normal cartilage, might herald the start of the vicious cycle of OA. Imaging fluorescently-labelled *in situ* human chondrocytes by confocal scanning laser microscopy (CLSM), identified a small, but potentially important population of abnormally-shaped chondrocytes^{9.10}. They exhibit cytoplasmic processes, the cells resembling a fibroblastic rather than a chondrocyte phenotype¹¹ which might reflect or lead to deleterious matrix metabolism¹². Abnormal chondrocyte morphology correlated with increased cell-associated IL-1 β , decreased chondron-localised collagen type VI¹³ and increased collagen type I¹⁴. It is possible that IL-1 β stimulation results in localised aggrecan depletion, the development/acceleration of abnormal

morphology and a fibro-cartilageous phenotype. Thus in non-degenerate human cartilage, these peculiar chondrocytes may possess increased ADAMTS-4 levels in contrast to normal (elliptical/rounded) chondrocytes. Alterations to ADAMTS-4 levels associated with chondrocyte clusters is also of interest as proliferation is a characteristic of later OA and could cause additional ECM weakness.

Using CLSM imaging, fluorescently-labelled *in situ* chondrocytes were classified cell-by-cell into those with (a) normal morphology, (b) abnormal morphology (\geq 1 process/cell) and (c) cells (\geq 4) in a cluster, within grade 0 (G0;normal non-degenerate) and grade 1 (G1;mild OA) human cartilage. On the same cells, we semi-quantitatively assessed ADAMTS-4 immuno-fluorescence (IF) and determined its relationship with chondrocyte morphology. The results demonstrated marked heterogeneity in the morphology and ADAMTS-4 levels of human chondrocytes. In macroscopicallynormal cartilage, a small but significant population of abnormal chondrocytes was present possessing higher levels of ADAMTS-4 compared to normal or clustered cells. These early changes to ADAMTS-4 levels might indicate ECM regions more sensitive to mechanical load and focal points for OA cartilage degeneration.

Methods, Results and Discussion

Femoral heads (FHs) were obtained from N=14 patients (8 females;6 males (range 44-89yrs; mean 71yrs)) undergoing surgery for femoral neck fracture. Ethical permission (Tissue Governance (NHS), Lothian) and consent were obtained. Cartilage areas were visually graded G0 or G1 using OARSI criteria and explants taken¹¹. Chondrocyte morphology was identified using 5chloromethylfluorescein-diacetate (CMFDA). Spheroidal/elliptical cells without cytoplasmic processes were classified as normal cells. A cytoplasmic process was defined as a CMFDA-labelled protrusion of $\geq 2\mu m$. Chondrocyte clusters possessed ≥ 4 cells within the lacunar space. Sections were incubated with ADAMTS-4 antibody (PA1-1749A, Invitrogen;1:100), then incubated with secondary antibody (AlexaFluor[™] ab175471, Abcam;1:200). Sections were mounted (propylgallate;Sigma-Aldrich, Dorset), imaged (Zeiss LSM800) and analysed (Imaris[™], Oxford Instruments, U.K.). A section from each explant was used as a negative control with background secondary antibody fluorescence subtracted to identify specific labelling. A cell-by-cell mask selection allowed

Cartilage

analysis of cell-specific (punctate) immuno-fluorescence which localised with CMFDA labelling. For cell clusters, the selection encompassed the whole cluster and fluorescence assessed on a 'per cell' basis. Fluorescence intensity was presented in Relative Fluorescence Units (RFU). Asterisks represent $P \le 0.05^*$, $P \le 0.01^{**}$, and $P \le 0.001^{***}$. Femoral heads (N) and cells (n) were presented as [N(n)].

There were clear differences between cells in G0 and G1 cartilage (Fig.1A(a,b)). At low magnification, the majority of cells in G0 were normal, however at high magnification, abnormal chondrocytes were observed (Fig.1A(a)(iii)). In G1, clustering and cytoplasmic processes were detected at low and high magnification (Fig.1A(b)(i-iv)). Chondrocyte morphology classified into normal, abnormal or clusters was performed by eye. There was a decrease (90% to 50%) in normal chondrocytes between G0 and G1 (P<0.01;Fig.1B(a)). However, there was ~2-fold increase in abnormal cells (P<0.05;Fig.1B(b)), and a >6-fold increase in cells within a cluster (P<0.001;Fig.1B(c)). Occasionally, these cells exhibited processes (Fig.1A(b)(ii)) and were classified as a cell in a cluster. The average length of processes increased from 3.81±0.67µm to 6.44±1.16µm (G0 *vs* G1 cartilage [4(77);P=0.0125)].

Having identified the chondrocyte morphologies, their association with ADAMTS-4 levels was assessed. There was clear ADAMTS-4 immuno-fluorescence (Fig.2A(ii&iv)) which matched the CMFDA-labelled cells, appearing as punctate labelling closely delineating the same size/morphology suggesting cell-associated labelling (Fig.2A(i&iii)). CLSM visualisation highlighted the heterogeneous nature of ADAMTS-4 labelling. Both diffuse and punctate labelling was evident with strong labelling in some cells close to weakly-labelled cells (Fig. 2A(ii&iv)). For all cell types assessed in either G0 or G1 cartilage, there was no difference between mean or punctate fluorescence levels (P=0.5245; P=0.4080 respectively). This indicated mean levels over a relatively large area or when measured as cell-associated protein did not change with early cartilage degeneration. However cellassociated (punctate) labelling was higher (P<0.001) in both G0 and G1 compared to mean levels and this was expected since it related to cell-specific labelling which covered smaller and more intense areas of labelling. Clearly, this generalised chondrocyte labelling could mask the heterogeneous distribution of ADAMTS-4 between the various morphologies (Fig.1A). Accordingly, >4000 cells within G0 and G1 cartilage were imaged, and morphology and ADAMTS-4

immunofluorescence analysed cell-by-cell. Despite the data spread, abnormal cells demonstrated higher intensity than normal (*P*=0.0440) or clustered chondrocytes (*P*<0.0001;Fig.2B(i)).

With cartilage degeneration, there was a marked increase in the proportion of abnormal cells and clustered cells (Fig.1B(a-c)). Thus in G1 cartilage it was possible increased numbers of abnormal cells with greater levels of ADAMTS-4 would be offset by the increased number of cell clusters which had lower levels of the enzyme. This could account for the lack of a difference between overall levels of the enzyme between G0 and G1 noted above. Accordingly, the percentages of chondrocytes in G0 and G1 cartilage with a given IF intensity were plotted (Fig.2B(ii)). While there was a broad distribution in both grades, the levels in G0 cartilage (with normal and abnormal cells, but negligible clusters) was higher and broader than that in G1 cartilage. For G1 cartilage, all three cell categories were present (Fig.1B(a-c)), but there was a higher proportion of cells in clusters possessing lower levels of ADAMTS-4 as reflected in the sharper lower IF intensity peak. There was no difference between ADAMTS-4 labelling for normal cells (P=0.9980), cells with processes (P>0.9999) or cells in a cluster between G0 and G1 (P=0.9744;[3(436)]) suggesting morphological/clustering properties of the cells determined ADAMTS-4 levels and not cartilage grade. Although we have graded cartilage, our description of a small population of morphologicallyabnormal chondrocytes in apparently G0 cartilage (Fig.1B(a)) raises an interesting guestion about cartilage grading. Chondrocyte death and clustering in histological sections are important criteria for cartilage grading however observing subtle changes in chondrocyte morphology requires different approaches such as those described here. We accept that a limitation is that the G0 cartilage studied here might have microscopic characteristics of very early cartilage degeneration and as such might not be 'truly' non-degenerate. Nevertheless we feel that the identification of aberrant chondrocytes provides an important insight into initial changes associated with cartilage degeneration.

CLSM and imaging identified marked heterogeneity in ADAMTS-4 levels which depended on chondrocyte shape and clustering. This approach assesses the responses of single *in situ* cells and revealed subtle and local properties of chondrocytes obscured with whole tissue samples. Morphologically-abnormal chondrocytes labelled more strongly for ADAMTS-4 compared to normal or clustered chondrocytes (Fig.2B(i)). As the chondrocyte population changed with cartilage degeneration (i.e. with more abnormal cells and clusters) this was reflected in a shift to left of the

Cartilage

distribution curve as there was a large number of cells in clusters with lower levels of ADAMTS-4 (Fig.2(B)(ii). There was also heterogeneous labelling in each of the chondrocyte categories but there was no a priori reason that cells in each category should behave identically. Examples showed chondrocytes with no clear ADAMTS-4 labelling beside strongly-labelled cells, and even cells within the same lacuna exhibiting varying levels of labelling (Fig.2A(iv)). This could be due to variations in primary and/or secondary antibody penetration, however heterogeneity was observed in single sections and images where all cells would be exposed to identical antibody levels. A more likely explanation could be that access of factors controlling ADAMTS-4 production are variable and dependent e.g. on local ECM permeability. While IL-1ß upregulates ADAMTS-4 gene expression in human chondrocytes and cartilage explants³, cell-associated levels of IL-1ß are very different between *in situ* human chondrocytes of varying morphology¹³. Thus IL-1 β availability either from intracellular metabolism or an inflammatory response, could be variable accounting for the heterogeneity in ADAMTS-4 levels. The estimated t_{1/2} of ADAMTS-4 exocytosis is ~220mins¹⁵ and it is possible that there are varying levels of ADAMTS-4 depending on local IL-1 β concentrations. We also do not know the aggrecan levels around chondrocytes, however as they may be reduced in the vicinity of morphologically-abnormal cells, this could lead to focal regions of mechanical weakness.

Acknowledgements; We are very grateful to Ms Fiona Gibson from Edinburgh Orthopaedics for coordinating consent, collection and delivery of femoral heads. We also thank Dr Anisha Kubasik-Thayil for assistance with the CLSM. Arthur Herren was funded through the ERASMUS exchange scheme between the University of Edinburgh and the Karolinska Institutet.

Authors: Arthur O.F. Herren¹, Anish K. Amin², and Andrew C. Hall³

¹Present address: Department of Physiology & Pharmacology, Karolinska Institutet, Sweden.

²Edinburgh Orthopaedics, Royal Infirmary of Edinburgh, 49 Little France Crescent,

NHS Lothian, Edinburgh EH16 4SA, UK.

³Deanery of Biomedical Sciences, University of Edinburgh, UK.

Correspondence to:

Dr Andrew C. Hall, PhD, BSc.

Deanery of Biomedical Sciences,

University of Edinburgh,

Hugh Robson Building,

George Square,

Edinburgh EH8 9XD,

Scotland, U.K. Phone + 44 (0)131 650 3263

FAX + 44 (0)131 650 2872

E.mail; a.hall@ed.ac.uk

Key words: chondrocyte, osteoarthritis, ADAMTS-4.

Perez.

References

1. Mease PJ, Hanna S, Frakes EP, Altman RD. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment. *J Rheumatol*. 2011;38:1546-5. https://doi.org/10.3899/jrheum.100759

2. Caterson B, Flannery CR, Hughes CE, Little CB. Mechanisms involved in cartilage proteoglycan catabolism. *Matrix Biol* 2000;19:333-344. <u>https://doi.org/10.1016/S0945-053X(00)00078-0</u>

3. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J-P, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. *Nat Rev Rheumatol* 2011;7:33-42. <u>https://doi.org/10.1038/nrrheum.2010.196</u>

4. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Hagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman Jr MC, Hollis GF, Newton RC, Magolda RL, Trzaskos JM, Arner EC. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. *Science* 1999:284(5420):1664-1666. https://doi.org/10.1126/science.284.5420.1664

5. Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: Key enzymes in osteoarthritis. *J Cell Biochem*. 2011;112(12):3507–14. <u>https://doi.org/10.1002/jcb.23298</u>

6. Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC, Griggs DW. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. *Arth Rheum.* 2007;56(2):575–85. <u>https://doi.org/10.1002/art.22334</u>

7. Naito S, Shiomi T, Okada A, Kimura T, Chijiiwa M, Fujit Y, Yatabe T, Komiya K, Enomoto H, Fujikwa K, Okada Y. Expression of ADAMTS-4 (aggrecanase-1) in human osteoarthritic cartilage. *Pathol. Intern*. 2007;57(11):703-711. <u>https://doi.org/10.1111/j.1440-1827.2007.02167.x</u>

8. Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, Flannery CR, Kanki K, Wang E, Peluso D, Yang Z, Majumdar MK, Morris EA. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. *Arth Rheum.* 2004;50(8):2547–58. <u>https://doi.org/10.1002/art.20558</u>

9. Bush PG, Hall AC. The volume and morphology of chondrocytes within non-degenerate and degenerate human articular cartilage. *Osteoarthr Cartil.* 2003;11(4):242–51. https://doi.org/10.1016/S1063-4584(02)00369-2

10. Karim A, Amin AK, Hall AC. The clustering and morphology of chondrocytes in normal and mildly degenerate human femoral head cartilage studied by confocal laser scanning microscopy. *J Anat.* 2018;232(4):686–98. <u>https://doi.org/10.1111/joa.12768</u>

11. Hall AC. (2019). The role of chondrocyte morphology and volume in controlling phenotype – implications for osteoarthritis, cartilage repair and cartilage engineering. *Curr. Top. Rheumatol.* 21:38 <u>https://doi: 10.1007/s11926-019-0837-6</u>

12. Benya PD, Padilla SR, Nimni ME. Independent regulation of collagen types by chondrocytes during the loss of differentiation function in culture. *Cell* 1978;15:1313–21. <u>https://doi.org/10.1016/0092-8674(78)90056-9</u>

13. Murray DH, Bush PG, Brenkel IJ, Hall AC. Abnormal human chondrocyte morphology is related to increased levels of cell-associated IL-1β and disruption to pericellular collagen type VI. *J Orthop Res.* 2010;28(11):1507–14. <u>https://doi.org/10.1002/jor.21155</u>

14. Styczynska-Soczka K, Amin AK, Hall AC. Cell-associated type I collagen in nondegenerate and degenerate human articular cartilage. *J Cell Physiol.* 2021;236(11):7672–81. https://doi.org/10.1002/jcp.30418

15. Yamamoto K, Owen K, Parker AE, Scilabra SD, Dudhia J, Strickland DK, Troeberg L, Nagase H. Low Density Lipoprotein Receptor-related Protein 1 (LRP1)-mediated Endocytic Clearance of a Disintegrin and Metalloproteinase with Thrombospondin Motifs-4 (ADAMTS-4). *J Biol Chem.* 2014;289(10):6464-6474 https://doi.org/10.1074/jbc.M113.545376

for per period

```
Page 9 of 10
                                 Cartilage
Herren et al (2023) Figure 1.
```



http://mc.manuscriptcentral.com/cart

Cartilage

Herren et al (2023) Figure 2.

(A)

